Mutant p53 Gain of Function: Why Many See It, Why Some Do not

IF 29.7 1区医学 Q1 ONCOLOGY

Cancer discovery Pub Date : 2025-04-27 DOI:10.1158/2159-8290.cd-24-1638

Guillermina Lozano, Carol Prives, Kanaga Sabapathy

引用次数: 0

Abstract

Summary: Mutations in the TP53 tumor-suppressor gene in human cancer are unique in that 60% to 70% are of the missense variety, resulting in a full-length protein that is often highly expressed in patients’ tumors. These missense mutant proteins often exhibit pro-oncogenic activities (referred to as gain of function) in mouse models and human cell lines and correlate with poor cancer prognosis in some cases.

查看原文本刊更多论文

突变型p53功能的获得：为什么很多人看到，为什么有些人看不到

摘要：人类癌症中TP53肿瘤抑制基因的突变是独特的，因为60%到70%是错义突变，导致全长蛋白在患者肿瘤中经常高表达。这些错义突变蛋白在小鼠模型和人类细胞系中经常表现出促癌活性（称为功能增益），并在某些情况下与不良的癌症预后相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer discovery ONCOLOGY-

CiteScore

22.90

自引率

1.40%

发文量

838

审稿时长

6-12 weeks

期刊介绍： Cancer Discovery publishes high-impact, peer-reviewed articles detailing significant advances in both research and clinical trials. Serving as a premier cancer information resource, the journal also features Review Articles, Perspectives, Commentaries, News stories, and Research Watch summaries to keep readers abreast of the latest findings in the field. Covering a wide range of topics, from laboratory research to clinical trials and epidemiologic studies, Cancer Discovery spans the entire spectrum of cancer research and medicine.